Seroprevalence of SARS-CoV-2 and risk factors for infection among children in Uganda: a serial cross-sectional study

- 3
- Irene Bagala*^{1,2}, Jane Frances Namuganga*², Patience Nayebare², Gloria Cuu², Thomas 4 Katairo², Isaiah Nabende², Samuel Gonahasa², Martha Nassali², Stephen Tukwasibwe², Grant 5 Dorsey³, Joaniter Nankabirwa^{1,2}, Sabrina Bakeera Kitaka¹, Sarah Kiguli¹, Bryan Greenhouse³, 6 Isaac Ssewanyana^{2,4}, Moses R Kamya,^{1,2} Jessica Briggs³ 7 8 9 *co-first authors 10 11 1 Makerere University College of Health Sciences, Kampala, Uganda 12 2 Infectious Diseases Research Collaboration, Kampala, Uganda 13 3 University of California, San Francisco, USA 14 4 Central Public Health Laboratory, Butabika, Uganda 15 16 Corresponding author: Irene Bagala [bglirene@gmail.com] 17 18 Keywords: COVID-19, SARS-CoV-2, seroprevalence, serosurvey, COVID-19 vaccination, 19 COVID-19 risk factors in children 20 21 22 ABSTRACT (300 words max): 23 24 Background: Understanding COVID-19's impact on children is vital for public health policy, yet
- 25 age-specific data is scarce, especially in Uganda. This study examines SARS-CoV-2
- 26 seroprevalence and risk factors among Ugandan children at two timepoints, along with COVID-
- 27 19-related knowledge and practices in households, including adult vaccination status.

- 29 Methods: Baseline surveys were conducted in 12 communities from April to May 2021 (post-
- 30 Alpha wave) and follow-up surveys in 32 communities from November 2021 to March 2022
- 31 (Omicron wave). Household questionnaires and blood samples were collected to test for malaria
- 32 by microscopy and for SARS-CoV-2 using a Luminex assay. Seroprevalence was estimated at
- both the survey and community level. Mixed-effects logistic regression models assessed the
- 34 association between individual and household factors and SARS-CoV-2 seropositivity in
- 35 children, adjusting for household clustering.

2	0
ত	ь

37	Results: More households reported disruptions in daily life at baseline compared to follow-up,
38	though economic impacts lingered. By the follow-up survey, 52.7% of adults had received at
39	least one COVID-19 vaccine dose. Overall seroprevalence in children was higher at follow-up
40	compared to baseline (71.6% versus 19.2%, p < 0.001). Seroprevalence in children ranged
41	across communities from 6-37% at baseline and 50-90% at follow-up. At baseline, children from
42	the poorest households were more likely to be infected. Increasing age remained the only
43	consistent risk factor for SARS-CoV-2 seroconversion at both timepoints.
44	
45	Conclusions: Results indicate that a larger number of children were infected by the Delta and
46	Omicron waves of COVID-19 compared to the Alpha wave. This study is the largest
47	seroprevalence survey in children in Uganda, providing evidence that most children were
48	infected with SARS-CoV-2 before the vaccine was widely available to pediatric populations.
49	Pediatric infections were vastly underreported by case counts, highlighting the importance of
50	seroprevalence surveys in assessing disease burden when testing and reporting rates are
51	limited and many cases are mild or asymptomatic.
52	
53	MANUSCRIPT:
54 55	Background
56	The emergence of the SARS-CoV-2 virus in 2019 led to a global pandemic in 2020, with
57	countries around the world grappling with its impact. Uganda registered its first case of COVID-
58	19 in March 2020, marking the onset of the Alpha wave (1). In recognition of the potential for
59	COVID-19 causing significant morbidity and mortality in Uganda, the government responded by
60	instituting lock-down measures including the closure of schools, workplaces, border crossings,
61	and travel restrictions on March 18, 2020 (2).

62 However, as in many other sub-Saharan African nations, reported cases in Uganda were 63 significantly lower than initially expected (3–5). As of March 14, 2024, only 172,149 confirmed 64 cases have been reported in Uganda (1), numbers that are likely to be a gross under-estimation 65 of the true extent of the country's COVID-19 disease burden because access to confirmatory 66 testing for SARS-CoV-2 was not widespread and existing surveillance systems were ill-67 equipped to capture all cases (6). Notably, there are few age-stratified data available to 68 understand the burden of COVID-19 infection in children, including in Uganda. 69 Understanding the true burden of COVID-19 infection in pediatric populations is 70 especially challenging because children are more likely to have asymptomatic or mild COVID-19 71 infection and may therefore be less likely to be captured by surveillance systems that rely on 72 case counts (7–9). Seroprevalence surveys, which capture both asymptomatic and symptomatic 73 infections, play a vital role in understanding the true burden of SARS-CoV-2 infection (6,10,11). 74 Evidence from other seroprevalence surveys in Uganda and sub-Saharan Africa suggest high 75 rates of infection despite low national case counts; however, there are no published studies that 76 focus on seroprevalence in children (10–13). Data from seroprevalence surveys can help 77 policymakers assess the scale of transmission among children and inform public health 78 strategies.

Herein we describe the seroprevalence of SARS-CoV-2 and risk factors for infection among children across Uganda using data from cross-sectional household surveys conducted at two timepoints; April-May 2021 (after the Alpha wave) and November 2021-March 2022 (during the Omicron wave). In addition, these surveys also collected data on COVID-19 related knowledge, attitudes, and practices from an adult member of the household.

84 Methods

85

86 Study sites and timeline

87 This COVID-19 sub-study was embedded within a cluster-randomized trial to evaluate 88 the impact of two types of long-lasting insecticidal bed nets (LLINs) distributed as part of 89 Uganda's 2020-2021 national universal coverage campaign. The parent study included 64 90 clusters from 32 districts (2 clusters per district). A cluster was defined as a target area 91 surrounding public health facilities with enhanced malaria surveillance, known as Malaria 92 Reference Centres (MRCs). Target areas included the village in which the MRC was located 93 and adjacent villages that met the following criteria: (1) did not contain another government-run 94 health facility, (2) located in the same sub-county as the MRC, and (3) similar incidence of 95 malaria as the MRC's village. All households within the MRC target areas were mapped and 96 enumerated to generate a sampling frame for the cross-sectional surveys. Baseline cross-97 sectional community surveys were carried out in the target areas of 12 of the 64 MRCs from 98 April to May 2021, and follow-up surveys were carried out in the target areas of all 64 MRCs 99 from November 2021 to March 2022, 12 months following LLIN distribution (Figure 2). For each 100 cluster for each survey, 50 households with at least one child aged 2-10 were randomly enrolled 101 from those enumerated, using criteria previously published (14).

For the cross-sectional surveys, a household questionnaire was administered to the heads of household or other designated adult using pre-programmed tablets. Information was gathered on characteristics of households and residents, proxy indicators of wealth including ownership of assets, and LLIN ownership. For this sub-study, additional questions on COVID-19 attitudes, beliefs, and behaviors were added. Questions about vaccination status were asked of the household head about every individual in the household.

108

109 Sample collection

During the baseline survey of 12 MRC target areas, a finger prick blood sample was
collected from all children in the household aged 2-10 who were present. During the follow-up

survey, sample collection was expanded, and finger prick blood samples were collected from all children less than 18 years of age from 32 of the 64 MRC target areas. At both timepoints, blood samples were used to prepare a thick blood smear and prepare a dried blood spot (DBS). For both cross-sectional surveys, informed consent was obtained at the time of the evaluation including consent for future use of biological specimens, along with assent if the child was 8 years old or older. Individual level demographic and clinical data were collected from all children eligible for sample collection.

119

120 Laboratory Methods

To determine the presence of malaria parasites, thick blood smears were stained with 2% Giemsa for 30 min and read by experienced laboratory technologists. A thick blood smear was considered negative when the examination of 100 high-power fields did not reveal asexual parasites. For quality control, all slides were read by a second microscopist and discrepant readings were settled by a third reviewer.

126 For serologic evaluation, serum was eluted from a 6-mm DBS punch using a previously 127 described method (15). To assess total IgG responses to the receptor-binding domain (RBD) of 128 the spike protein, a Luminex bead assay previously described for SARS-CoV-2 serologic 129 studies (13) was optimized for DBS samples. Samples were assayed at 1:400 dilution to 130 determine antibody seropositivity, with the results expressed as mean fluorescent intensity. A 131 standard curve using a pool of positive serum was included on each plate to normalize for plate-132 to-plate variations and to infer relative antibody concentrations using a 4-parameter logistic 133 model (16). For negative controls, 80 DBS were used from the PRISM-2 cohort study in Tororo 134 District, Uganda collected in 2017 and 2018 (17). For positive controls,151 DBS were used from 135 volunteers enrolled in the UCSF Long-term Impact of Infection with Novel Coronavirus study 136 (18).

137

138 Statistical Analysis

139 STATA (version 17) and R (version 4.3.1) were used for data analysis. Responses to the

- 140 household survey about COVID-19 knowledge, attitudes, and behaviors were tabulated for each
- survey time point as simple proportions and compared using the Chi-squared test. Survey data
- 142 were included for all 12 communities surveyed at baseline and for the 32 communities with
- 143 expanded sample collection at follow up.
- 144 To determine the cut off for seropositivity, receiver-operator curve analysis was performed using
- 145 R package ROCR (19) to maximize both sensitivity and specificity of the assay based on the
- relative antibody concentration data from positive and negative controls. A sample from an
- 147 individual was determined to be seropositive if the mean fluorescent intensity was above the
- 148 cutoff. Assay sensitivity was 94.7% and specificity was 97.5%. Raw SARS-CoV-2
- seroprevalence at each MRC was calculated as the number of samples that tested positive over
- all samples tested from that MRC. We then calculated seroprevalence at the MRC level
- 151 adjusted for sensitivity and specificity.

152

- 153 Univariate and multivariate mixed-effects logistic regression models were used to measure
- 154 associations between household-level and individual-level factors with SARS-CoV-2
- seropositivity among children, accounting for clustering within households. Statistical
- 156 significance was assessed using two-tailed tests with a p-value threshold of less than 0.05.
- 157 Confidence intervals for odds ratios were set at 95%.

158

159 Ethical approval

The parent (LLINEUP2, ClinicalTrials.gov: NCT04566510) study was approved by the
Institutional Review Boards (IRBs) at Makerere University School of Medicine Research and

162 Ethics Committee (SOMREC), the Uganda National Council for Science and Technology 163 (UNCST), the University of California San Francisco and London School of Hygiene and 164 Tropical Medicine. Written informed consent to participate in the study was obtained from adults 165 or from parents/guardians for their child(ren). A second written consent form was used to 166 consent adults or parents/guardians for the future use of biological specimens obtained during 167 the study. Written assent to participate in the study was also obtained from children aged 8 168 years and older. A request for waiver of consent to conduct laboratory analysis was obtained 169 from SOMREC. For this sub-study, laboratory analysis was only conducted on samples for 170 which participants had given consent for future use of biological specimens. 171 172 RESULTS 173 174 **Study Profile** 175 Figure 2 shows daily reported cases of SARS-CoV-2 at the national level; clear peaks in 176 reported cases are consistent with infections caused by the Alpha variant (December 177 2020 January 2021), the Delta variant (May July 2021), and the Omicron variant (December 178 2021-February 2022) (1). Data for this study came from cross-sectional surveys performed 179 across Uganda in the target area of 12 MRCs from 10 April to 6 May 2021 (blue bar, Figure 2) 180 and the target areas of 32 MRCs from 24 November 2021 to 27 March 2022 (green bar, Figure 181 2). Therefore, the baseline survey data were collected after the Alpha wave and before the 182 surge of the Delta wave, and the follow-up survey data was collected throughout the Omicron 183 wave. Details of the study participants with DBS samples collected at each survey time point are 184 shown in **Figure 1**. In the baseline survey, children ages 2-10 were eligible for sample 185 collection, while in the follow-up survey, all children <18 years of age were eligible for sample 186 collection. Serology data were successfully generated for 96.8% of eligible participants in the 187 baseline study and for 99.4% of eligible participants in the follow-up survey. At the baseline

survey, 423 (52.3%) of the children were ages 2-5 years and 386 (47.7%) of the children aged
6-10 years. During the follow-up survey, 561 (20.1%) of the children were aged less than 2
years, 973 (34.8%) between 2 to 5 years, 1026 (36.7%) between 6 to 10 years and 233 (8.3%)
between 11 to 17 years.

192 COVID-19 related knowledge, attitudes, and behaviors

193 Table 1 presents data on knowledge, perceptions and behaviors related to COVID-19 from the 194 baseline and the follow-up household surveys. Avoidance of crowds, increased hand washing, 195 and masking outside the home were reported at very high rates (>80%) during the baseline 196 survey and generally remained high, though there was less hand washing reported during the 197 Omicron wave (Table 1). Knowledge about the modes of transmission of COVID-19 was also 198 high; > 80% of household heads reported understanding that coughing/sneezing promoted the 199 spread of COVID-19. Face to face talking and indirect spread through fomites were also 200 correctly identified as routes of transmission, though fewer households were aware of fomites 201 as a possible means of transmission. More households reported disruptions in daily life in the 202 baseline survey compared to the follow-up survey (41.3% vs 25.6%). The largest disruptions in 203 daily life at baseline included lost income (21.5%), restricted movement (7.6%), children being 204 unable to attend school (4.6%), and not visiting friends or family (3.2%). All reported disruptions 205 in day-to-day life improved during the follow-up survey; however, 15.8% of households still 206 reported a loss of income, implying that the pandemic had an economic impact still felt at the 207 time of the follow up survey. Compared to the baseline survey, an improvement in ability to 208 travel was reported in the follow-up survey (63.4% vs 49.4% reporting difficulty traveling from 209 baseline to follow-up). Importantly, nearly half of household heads reported health facility 210 medication stockouts at baseline, and 33% reported staff shortages. Both availability of 211 medicines and staff were improved at follow-up but rates of disrupted services remained high. 212

			214	-		
Questions	Categories	Baseline survey (n = 634)	Follow-up surve 21 5 (n = 1729)			
Do you avoid crowds?	1	539 (85.0%)	1,545 (89 24%6			
Do you wash your hands more often?		4 9 9 9 (5 4 9 9 ()	-			
Do you wear a mask outside the home?	551 (86.9%)	1,280 (74,0%) 217				
	553 (87.2%)	1,419 (82.1%) 218	-			
	Coughing/sneezing	514 (81.1%)	1,530 (88 21⁄9	,		
Can COVID-19 be spread the	Face to face talking	415 (65.5%)	1,036 (59.9%)			
following way?	Indirect contact / fomites	128 (20.2%)	523 (30 2 220)			
	Doesn't know how COVID-19 is spread	23 (3.6%)	^{19 (1.1%)} 221	4		
	Greater food insecurity	15 (2.4%)	23 (1.3%)	1		
	Lost income	136 (21.5%)	274 (15.8%)	,		
	Not visiting friends or family	20 (3.2%)	11 (0.6%) 3	va		
	Higher prices	4 (0.6%)	^{16 (0.9%)}			
If your daily life has been changed by	Children at home from school Masks required (hand washing (social	31 (4.9%)	31 (1.8%)			
COVID-19, how has it changed?	distancing	9 (1.4%)	^{6 (0.3%)} 225			
	Movement restricted	48 (7.6%)	63 (3.6 %)			
	Lack of medication	0 (0%)	^{0 (0%)} 226			
	Fear of getting sick	11 (1.7%)	28 (1.6%)			
		2 (0.3%)	¹² (0.7%) 227			
Travel has been more difficult due to C	OVID-19 lockdowns	402 (63.4%)	854 (49.4%) 228],		
Changes noticed regarding care	No medications available	303 (47.8%)	455 (26.3%)			
available at local health facilities	Less staff available	211 (33.3%)	221 (12. 22)			
			230]		

213 Table 1. COVID-19 related knowledge, attitudes, and behaviors

231 RS-CoV-2 infection was not available in Uganda at the time of the baseline survey and was not 232 available for children during the time period of either survey (20). Vaccination status was 233 assessed in follow-up surveys from November 2021 to March 2022 by asking the household 234 head if each individual member of the household was vaccinated. 1,753 individuals out of 3,326 235 adults (52.7%) were reported to be vaccinated. The majority of individuals received one dose, 236 while 24.6% had received two doses. The most commonly received first vaccine was the Astra-237 Zeneca vaccine (40.5%), followed by the Johnson and Johnson vaccine (29.5%) and mRNA 238 vaccines (Pfizer, Moderna, or not otherwise specified) (17.4%) (Supplemental Table 1). Astra-

- 239 Zeneca remained the most commonly received second vaccine (59.9%) followed by
- 240 Sinovac/Sinopharm (18.3%).
- 241

242 Seroprevalence of SARS-CoV-2 in children at baseline and follow-up surveys

- 243 SARS-CoV-2 seroprevalence in children was estimated in the target areas around each MRC
- for both survey timepoints (Figure 3). Overall adjusted seroprevalence was higher at follow-up
- compared to baseline (71.6% versus 19.2%, p < 0.001). In the baseline survey, seroprevalence
- in the communities surrounding the surveyed MRCs ranged from 5.7% at Butagaya to 37.3% at
- 247 Namokora. Seroprevalence increased at all sites in the follow-up survey; the lowest
- seroprevalence at follow-up was 50.0% at Kigandalo, and 9 sites had a seroprevalence >81% in
- the follow-up survey, with the highest seroprevalence at Kibaale (89.6%).

	Baseline survey					Follow-up survey					
.,	Categories	Seroprevalence	Univariate analysis*		Multivariate analysis*			Univariate analysis*		Multivariate analysis*	
Variable			OR (95% CI)	p-value	aOR (95% CI)	p-value	- Seroprevalence	OR (95% CI)	p-value	aOR (95% CI)	p-value
Individual level	risk factors								h va		
	<u><</u> 2						371/561 (66.1%)	reference g	roup d	reference §	group
Age in years	3-5	68/423 (16.1%)	reference g	roup	reference g	roup	695/973 (71.4%)	1.39 (1.05-1.85)	0.02	1.42 (1.07-1.90)	0.015
	6-10	89/386 (23.1%)	1.72 (1.13-2.64)	0.01	1.69 (1.11-2.57)	0.02	797/1026 (77.7%)	2.03 (1.52-2.72)	0.00	2.11 (1.56-2.84)	0.000
	11-17						190/233 (81.6%)	3.13 (1.95-5.04)	0.00	3.16 (1.96-5.09)	0.000
	Male	72/401 (18.0%)	reference g	roup	reference group		973/1340 (72.6%)	reference group		reference group	
Gender	Female	85/408 (20.8%)	1.21 (0.81-1.81)	0.35	1.16 (0.78-1.74)	0.46	1080/1453 (74.3%)	1.16 (0.94-1.44)	0.1	1.11 (0.89-1.38)	0.34
Parasitemia by	No	115/588 (19.6%)	reference group		reference group		1579/2151 (73.4%)	reference group		reference g	group
microscopy	Yes	42/220 (19.1%)	0.82 (0.60-1.5)	0.82	0.83 (0.52-1.32)	0.43	474/642 (73.8%)	1.04 (0.80-1.34)	0.79 aut	0.89 (0.68-1.17)	0.42
Household level	risk factors								hor/funde	2	
	Least poor	36/260 (13.9%)	reference group		reference group		772/1037 (74.5%)	reference group သူရဲ့		, reference group	
Wealth index	Middle	54/282 (19.2%)	1.51 (0.89-2.56)	0.125	1.55 (0.88-2.72)	0.128	652/896 (72.8%)	0.96 (0.72-1.29)	0.79 h	, 5 0.89 (0.65-1.22)	0.48
	Poorest	67/265 (25.3%)	2.27 (1.34-3.84)	0.002	2.51 (1.37-4.60)	0.003	629/860 (73.1%)	0.98 (0.73-1.31)		5 0.82 (0.57-1.17)	0.27
House	Modern	44/215 (20.5%)	reference g	roup	reference group 8		831/1144 (72.6%)			reference group	
construction	Traditional	113/594 (19.0%)	0.88 (0.55-1.42)	0.62	0.61 (0.36-1.06)	0.08	1222/1649 (74.1%)	1.10 (0.86-1.41)		1.00 (0.71-1.41)	0.99
Number of	<2	30/185 (16.2%)	reference g	roup	reference group		390/527 (74.0%)	reference group		z reference group	
residents per	2-3	77/399 (19.3%)	1.29 (0.75-2.23)	0.36	1.11 (0.64-1.94)	0.71	1097/1498 (73.2%)	- 0.96 (0.70-1.31)	0.79	1.00 (0.72-1.53)	0.99
sleeping	>3	50/225 (22.2%)	1.58 (0.86-2.90)	0.14	1.32 (0.71-2.46)	0.39	566/768 (73.7%)	1.00 (0.70-1.44)	1.00 tr	š 1.05 (0.71-1.53)	0.82
Presence of windows	Uncovered windows	14/62 (22.6%)	reference group		reference group		59/92 (64.1%)	reference group		reference group	
	Covered windows	62/360 (17.2%)	0.67 (0.30-1.49)	0.32	62/360 (17.2%)	0.48	1000/1380 (72.5%)	1.50 (0.76-2.97)	0.25 0.25	1.38 (0.69-2.77)	0.36
	No windows present	81/387 (20.9%)	0.88 (0.40-1.93)	0.74	81/387 (20.9%)	0.58	994/1321 (75.3%)	1.88 (0.95-4.62)	0.07 O	5 1.97 (0.96-4.02)	0.64
252 253									lity.	5 5 5 4	

Table 2. Risk factors associated with seropositivity to SARS-COV-2 among Ugandan children at baseline and follow-up surveys

257 Individual and household level risk factors associated with seropositivity to SARS-COV-2

among Ugandan children

- 259 **Table 2** presents associations between individual and household risk factors and SARS-CoV-2
- seroprevalence among children in Uganda by univariate and multivariate analysis. At baseline,
- older age was associated with seroconversion (aOR 1.69, CI 1.11-2.57). In addition, children in
- the poorest households were more likely to have seroconverted compared to those in the
- 263 wealthiest households (aOR 2.51, CI 1.37 4.60). At follow-up, only increasing age was
- associated with SARS-CoV-2 seroconversion; there was no longer an association between
- 265 household wealth index and seroconversion.

Gender was not associated with seroconversion at baseline or at follow up. Microscopic malaria parasitemia had no association with SARS-CoV-2 seroconversion at either survey timepoint. At the household level, there was no association between house construction type, household crowding as measured by the number of residents per room for sleeping, or type of windows and SARS-CoV-2 seroprevalence at baseline or follow up.

271 Discussion

272 Results from the study indicate a drastic increase in the SARS-CoV-2 seroprevalence in 273 children from the baseline survey to the follow up survey, indicating that a larger proportion of 274 children were infected by the Delta and Omicron waves of COVID-19 compared to the Alpha 275 wave. Overall seroprevalence at the follow-up survey was 72%, showing that the majority of 276 children had been infected by SARS-CoV-2 by early 2022. Older age was associated with 277 increasing SARS-CoV-2 seroprevalence both at baseline and during the follow-up survey. 278 Interestingly, in the baseline survey children from the poorest households were more likely to 279 have been infected by SARS-CoV-2 compared to children from the wealthiest households, but 280 this association was no longer evident later in the epidemic after additional waves of infection. In

addition, disruptions to daily life and access to medications and healthcare were more
significant earlier in the epidemic but improved over time, with the exception of lingering
economic impacts such as lost income. COVID-19 vaccination had reached over half of
surveyed adults by the time of the follow-up survey.

285

286 While there are no other published studies from Uganda on SARS-CoV-2 seroprevalence 287 exclusively in children, our finding of an overall seroprevalence of 72 % in a survey conducted 288 from November 2021-March 2022 (during the Omicron wave) is consistent with seroprevalence 289 studies conducted in Uganda in other age groups. A blood donor study that evaluated donors 290 aged 16 and over between October 2019 and April 2022 found that N and S seropositivity 291 increased throughout the pandemic, reaching 83% in January-April 2022 (12). A cohort study in 292 eastern Uganda that included both children and adults found that by the end of the Delta wave 293 (before widespread vaccination) 68% of the cohort had been infected, and after the Omicron 294 wave, 85% had been infected (13). While the seroprevalence estimate of 72% from this study is 295 lower than that found by the two other studies in Uganda after the Omicron wave, this might be 296 expected since this study was conducted during and not after the Omicron wave. In addition, 297 since increasing age is correlated with increasing seroprevalence, a lower seroprevalence may 298 be expected in a study that only includes children compared to studies including adults.

299

The finding that increasing age is associated with higher seroprevalence in children is in agreement with seroprevalence studies in Uganda and elsewhere that have indicated seroprevalence is lowest in young children (8,11–13,21–23). Higher seroprevalence with increasing age could be due to differences in behavior, with older children more likely to attend gatherings outside the household (24,25), immunity (26–28), or case severity (7,29,30). We also found evidence that children from poorer households were more likely to be infected with SARS-CoV-2 earlier in the pandemic. This is consistent with studies from other countries where

lower socioeconomic status was associated with a higher risk of infection early in the pandemic
(21,25,31). However, by the time of the follow-up survey, this association was no longer
evident, likely because the majority children had been infected. While it is possible that the
poorest children remained at higher risk and were re-infected at higher rates than children in
wealthier households, we were unable to test this hypothesis.

312

313 Survey findings indicated severe disruptions in daily life, including inability to travel and lack of 314 access to medications at local public health facilities. Other significant reported disruptions 315 included loss of income and food insecurity. These disruptions improved over time but had not 316 normalized to the pre-COVID era by the follow-up survey. This is consistent with findings in a 317 previous study in Uganda, Ghana and other low income countries that reported negative effects 318 on finances and food insecurity as well as limited access to medical services during the COVID-319 19 pandemic (32–35). Previous studies have also reported disruptions in medical service 320 provision including stockouts of drugs (35) and disruptions in health service utilization (36). One 321 modeling study using district-level DHIS2 data from Uganda reported negative effects of 322 COVID-19 on utilization of health services, including outpatient attendance at public health 323 facilities and child health services, which were most severe early in the pandemic (37). This is in 324 contrast with another study by Namuganga et al. showing no major effects on the total number 325 of visits to 17 sentinel malaria surveillance outpatient health facilities in the first year after the 326 COVID-19 pandemic (2). Most studies that do report disruptions due to the COVID-19 327 pandemic report the highest effect in the earliest months of the pandemic, consistent with the 328 trend seen in this study and with the timing of the strictest lockdown policies in Uganda.

329

Our study is the largest seroprevalence survey in children in Uganda, providing evidence that
 most children were infected with SARS-CoV-2 before the vaccine was available to pediatric
 populations. Though only 12 districts were included in the baseline survey, data was available

333 from 32 districts in the follow-up survey, providing good geographic representation of most 334 regions in Uganda except for the southwest. A limitation is that SARS-CoV-2 seroprevalence 335 may have been underestimated in this study because SARS-CoV-2 antibodies wane over time, 336 particularly in asymptomatic or mild infection (38,39). In addition, most study sites were rural, 337 and therefore some more urban areas such as Wakiso District and Kampala that registered 338 higher numbers of SARS-CoV-2 cases (due to higher transmission or better access to testing) 339 during pandemic waves were not represented in this survey. This would also likely bias our 340 seroprevalence estimate toward underestimation. Our study highlights the usefulness of 341 seroprevalence surveys to estimate the true burden of infection, especially in rural populations 342 with less access to molecular testing for SARS-CoV-2 where using case reports alone would 343 severely underestimate the burden of SARS-CoV-2 infection in children. 344 345 Conclusions

346 In summary, SARS-CoV-2 seroprevalence among children in Uganda was high by early 2022, 347 providing evidence that the majority of children in Uganda were infected before the availability of 348 pediatric vaccination. Assessment of risk factors associated with SARS-CoV-2 infection 349 revealed increasing risk with increasing age, and higher risk in poorer children. These findings 350 may be useful to direct public health preventative strategies to protect vulnerable pediatric 351 populations in the next global pandemic. In addition, because COVID-19 disease in children is 352 often asymptomatic or mild and molecular testing for infection was not easily accessible, case 353 reports of infection in children vastly underrepresented the true infection rate in children in 354 Uganda. Seroprevalence surveys remain an important way of assessing the true burden of 355 disease when testing and reporting rates are not readily available.

356

357

- 360 FIGURE AND TABLE TITLES AND LEGENDS:
- 361
- 362 Figure 1: Study profile of participants enrolled in the study
- 363 Figure 2. Timing of the baseline (blue) and follow-up (green) cross-sectional surveys.
- 364
- 365 Table 1. COVID-19 related knowledge, attitudes, and behaviors
- 366
- 367 Figure 3. SARS-CoV-2 seroprevalence in the target areas surrounding MRCs in the
- 368 baseline and follow-up cross-sectional surveys.
- 369 **A.** RBD seroprevalence in children ages 2-10 in the baseline survey. **B.** RBD seroprevalence in
- 370 children 0-17 in the follow-up survey.
- 371
- 372 Table 2. Risk factors associated with seropositivity to SARS-COV-2 among Ugandan
- 373 children at baseline and follow-up surveys
- 374
- 375
- 376
- 377
- 378
- 379
- 380
- 381
- 382
- 383
- 384

385 DECLARATIONS

386 Ethical approval and consent to participate

- 387 All methods were carried out in accordance with relevant guidelines and regulations including
- 388 the Declaration of Helsinki. Study procedures were approved by Institutional Review Boards
- 389 (IRBs) at Makerere University School of Medicine Research and Ethics Committee (SOMREC),
- 390 the Uganda National Council for Science and Technology (UNCST), the University of California
- 391 San Francisco and London School of Hygiene and Tropical Medicine. Written informed consent
- 392 to participate in the study was obtained from adults or from parents/guardians for their
- 393 child(ren). A second written consent form was used to consent adults or parents/guardians for
- the future use of biological specimens obtained during the study. Written assent to participate in
- the study was also obtained from children aged 8 years and older. A request for waiver of
- 396 consent to conduct laboratory analysis was obtained from SOMREC.

397 Author Contributions

- 398 IB, JFN, and JB drafted the manuscript; IB, JFN, BG, JB, ST, and IS conceived the idea; JB and
- 399 IB performed the analysis; PN, GC, TK and ST performed laboratory assays; the LLINEUP2
- 400 study staff (SG, MN, JFN and IN) performed the cross-sectional surveys; BG, IS, JB, MK, JN
- 401 and GD obtained funding; JB, IS, MK, SK, SBK, and JN provided supervision over study staff,
- 402 laboratory work, and analysis; everyone reviewed the manuscript and edited.
- 403 Funding
- 404 We acknowledge sources of funding support including Makerere University Research and
- 405 Innovations Fund (MAKRIF/DVCFA/026/20) (IB, JFN, JN, MK, PN, IN); Fogarty International
- 406 Center of the National Institutes of Health (D43TW010526) (IB, JFN, GC, PN, TK, SG, MN, Dr.
- 407 ST); the Bill and Melinda Gates Foundation, INV-017893 and INV-023690 (JB, IS, BG); and

408 NIH/NIAID (K23 AI166009) to JB.

409 **Competing Interest Declaration**

410 The authors have no competing interests.

- 411
- 412

413 **REFERENCES**

- World Health Organization. Coronavirus (COVID-19) Dashboard, Uganda [Internet]. [cited
 2024 Mar 14]. Available from: https://covid19.who.int/region/afro/country/ug
- Ananuganga JF, Briggs J, Roh ME, Okiring J, Kisambira Y, Sserwanga A, et al. Impact of
 COVID-19 on routine malaria indicators in rural Uganda: an interrupted time series
 analysis. Malar J. 2021 Dec 20;20(1):1–11.
- Massinga Loembé M, Tshangela A, Salyer SJ, Varma JK, Ouma AEO, Nkengasong JN.
 COVID-19 in Africa: the spread and response. Nat Med. 2020 Jul;26(7):999–1003.
- 4. Salyer SJ, Maeda J, Sembuche S, Kebede Y, Tshangela A, Moussif M, et al. The first and
 second waves of the COVID-19 pandemic in Africa: a cross-sectional study. Lancet.
 2021;397(10281):1265.
- Bamgboye EL, Omiye JA, Afolaranmi OJ, Davids MR, Tannor EK, Wadee S, et al. COVID19 Pandemic: Is Africa Different? J Natl Med Assoc. 2021 Jun;113(3):324–35.
- 426 6. Tessema SK, Nkengasong JN. Understanding COVID-19 in Africa. Nat Rev Immunol.
 427 2021;21(8):469.
- 428 7. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 Infection in Children. N
 429 Engl J Med. 2020 Apr 23;382(17):1663–5.
- Viner RM, Mytton OT, Bonell C, Melendez-Torres GJ, Ward J, Hudson L, et al.
 Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With
 Adults: A Systematic Review and Meta-analysis. JAMA Pediatr. 2021 Feb 1;175(2):143–
 56.
- 434 9. Li J, Thoon KC, Chong CY, Maiwald M, Kam KQ, Nadua K, et al. Comparative analysis of
 435 symptomatic and asymptomatic SARS-CoV-2 infection in children. Ann Acad Med
 436 Singapore. 2020 Aug;49(8):530–7.
- 437 10. Chisale MRO, Ramazanu S, Mwale SE, Kumwenda P, Chipeta M, Kaminga AC, et al.
 438 Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-439 analysis. Rev Med Virol. 2022 Mar;32(2):e2271.
- 11. Naeimi R, Sepidarkish M, Mollalo A, Parsa H, Mahjour S, Safarpour F, et al. SARS-CoV-2
 seroprevalence in children worldwide: A systematic review and meta-analysis.
 EClinicalMedicine. 2023 Feb;56:101786.
- Bloch EM, Kyeyune D, White JL, Ddungu H, Ashokkumar S, Habtehyimer F, et al. SARSCoV-2 seroprevalence among blood donors in Uganda: 2019–2022. Transfusion . 2023 Jul
 1;63(7):1354–65.
- Briggs J, Takahashi S, Nayebare P, Cuu G, Rek J, Zedi M, et al. Seroprevalence of
 Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022. JAMA
 Netw Open. 2023 Feb 1;6(2):e2255978.

- 449 14. Okiring J, Gonahasa S, Nassali M, Namuganga JF, Bagala I, Maiteki Sebuguzi C, et al.
 450 LLIN Evaluation in Uganda Project (LLINEUP2)—Factors associated with coverage and
 451 use of long lasting insecticidal nets following the 2020–21 national mass distribution
 452 campaign: a cross-sectional survey of 12 districts. Malar J. 2022 Oct 19;21(1):1–12.
- 453 15. Wu L, Hall T, Ssewanyana I, Oulton T, Patterson C, Vasileva H, et al. Optimisation and
 454 standardisation of a multiplex immunoassay of diverse Plasmodium falciparum antigens to
 455 assess changes in malaria transmission using sero-epidemiology. Wellcome Open
 456 Research [Internet]. 2019 [cited 2023 Nov 12];4. Available from:
- 457 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255915/
- 458 16. Website [Internet]. Available from: Github. Flexfit: flexible format standard curve fitting and
 459 data processing (R Package). Accessed July 31, 2022.
 460 https://github.com/EPPIcenter/flexfit
- 17. Nankabirwa JI, Bousema T, Blanken SL, Rek J, Arinaitwe E, Greenhouse B, et al.
 Measures of malaria transmission, infection, and disease in an area bordering two districts
 with and without sustained indoor residual spraying of insecticide in Uganda. PLoS One
 [Internet]. 2022 Dec 30 [cited 2024 Apr 28];17(12). Available from:
 https://pubmed.ncbi.nlm.nih.gov/36584122/
- Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, et al. SARS-CoV-2 antibody
 magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv
 [Internet]. 2021 Jul;7(31). Available from: http://dx.doi.org/10.1126/sciadv.abh3409
- 469 19. Website [Internet]. Available from: Sing T, Sander O, Beerenwinkel N, Lengauer T (2005).
 470 "ROCR: visualizing classifier performance in R." Bioinformatics, 21(20), 7881.
 471 http://rocr.bioinf.mpi-sb.mpg.de.
- 472 20. Ministry of Health | Government of Uganda [Internet]. 2021 [cited 2024 Mar 31]. Update on
 473 covid-19 vaccination in Uganda Ministry of Health. Available from:
 474 https://www.health.go.ug/cause/update-on-covid-19-vaccination-in-uganda/
- 475 21. Sebastian T, Carlson JJ, Gaensbauer J, Podewils LJ. Epidemiology and Transmission
 476 Dynamics of COVID-19 in an Urban Pediatric US Population. Public Health Rep. 2022 Jul
 477 4;137(5):1013–22.
- 478 22. Misra P, Kant S, Guleria R, Rai SK, Kishore S, Baidya S, et al. Serological prevalence of 479 SARS-CoV-2 antibody among children and young age group (between 2 and 17 years) in 480 India: An interim result from a large multicentric population-based seroepidemiological 481 study. Journal of Family Medicine and Primary Care. 2022 Jun;11(6):2816.
- 482 23. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV 483 POP): a population-based study. Lancet. 2020 Aug 1;396(10247):313–9.
- 484 24. Hobbs CV. Factors Associated with Positive SARS-CoV-2 Test Results in Outpatient
 485 Health Facilities and Emergency Departments Among Children and Adolescents Aged 18
 486 Years Mississippi, September–November 2020. MMWR Morb Mortal Wkly Rep
 487 [Internet]. 2020 [cited 2024 Mar 15];69. Available from:
- 488 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950e3.htm

- 489 25. Reicher S, Ratzon R, Ben-Sahar S, Hermoni-Alon S, Mossinson D, Shenhar Y, et al.
 490 Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel. Eur J Epidemiol.
 491 2021;36(7):727.
- 492 26. Rotulo GA, Palma P. Understanding COVID-19 in children: immune determinants and post 493 infection conditions. Pediatr Res. 2023 Mar 6;94(2):434–42.
- 494 27. Yoshida M, Worlock KB, Huang N, Lindeboom RGH, Butler CR, Kumasaka N, et al. Local
 495 and systemic responses to SARS-CoV-2 infection in children and adults. Nature.
 496 2022;602(7896):321.
- 497 28. Weisberg SP, Connors TJ, Zhu Y, Baldwin MR, Lin WH, Wontakal S, et al. Distinct
 498 antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical
 499 spectrum. Nat Immunol. 2021 Jan;22(1):25.
- Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a
 better prognosis than adults. Acta Paediatr. 2020 Jun;109(6):1088–95.
- She J, Liu L, Liu W. COVID-19 epidemic: Disease characteristics in children. J Med Virol.
 2020 Jul;92(7):747–54.
- 31. O'Neill B, Kalia S, Hum S, Gill P, Greiver M, Kirubarajan A, et al. Socioeconomic and
 immigration status and COVID-19 testing in Toronto, Ontario: retrospective cross-sectional
 study. BMC Public Health [Internet]. 2022 May 29 [cited 2024 Mar 11];22(1). Available
 from: https://pubmed.ncbi.nlm.nih.gov/35643450/
- 32. Pattnaik J, Jalongo MR. The Impact of COVID-19 on Early Childhood Education and Care:
 International Perspectives, Challenges, and Responses. Springer Nature; 2022. 505 p.
- 33. Nuwematsiko R, Nabiryo M, Bomboka JB, Nalinya S, Musoke D, Okello D, et al.
 Unintended socio-economic and health consequences of COVID-19 among slum dwellers in Kampala, Uganda. BMC Public Health. 2022 Jan 13;22(1):88.
- 513 34. Josephson A, Kilic T, Michler JD. Socioeconomic impacts of COVID-19 in low-income countries. Nat Hum Behav. 2021 May;5(5):557–65.
- St. Kabwama SN, Wanyenze RK, Kiwanuka SN, Namale A, Ndejjo R, Monje F, et al.
 Interventions for Maintenance of Essential Health Service Delivery during the COVID-19
 Response in Uganda, between March 2020 and April 2021. Int J Environ Res Public Health
 [Internet]. 2022 Sep 30;19(19). Available from: http://dx.doi.org/10.3390/ijerph191912522
- 36. Andia-Biraro I, Baluku JB, Olum R, Bongomin F, Kyazze AP, Ninsiima S, et al. Effect of
 COVID-19 pandemic on inpatient service utilization and patient outcomes in Uganda. Sci
 Rep. 2023 Jun 15;13(1):9693.
- 37. Angeles G, Silverstein H, Ahsan KZ, Kibria MG, Rakib NA, Escudero G, et al. Estimating
 the effects of COVID-19 on essential health services utilization in Uganda and Bangladesh
 using data from routine health information systems. Front Public Health. 2023 Sep
 27;11:1129581.
- 526 38. Khaitan A, Datta D, Bond C, Goings M, Co K, Odhiambo EO, et al. Level and Duration of

- 527 IgG and Neutralizing Antibodies to SARS-CoV-2 in Children with Symptomatic or 528 Asymptomatic SARS-CoV-2 Infection. Immunohorizons. 2022 Jun 1;6(6):408–15.
- 39. Javier Ibarrondo F, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et
 al. Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J
 Med [Internet]. 2020 Jul 21 [cited 2024 Mar 15]; Available from:
- 532 https://www.nejm.org/doi/full/10.1056/nejmc2025179





